Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04227535
Active, not recruiting Observational

Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Pathogenesis 2

NCT04227535 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2020-02-03
Last updated
2023-04-28

Condition(s) studied

Rheumatoid ArthritisInterstitial Lung Disease

Study summary

The overall goal of this study is to identify risk and prognosis factors of Interstitial Lung Disease (ILD) in patients with rheumatoid arthritis (RA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
SELECTION OF CASES : Inclusion Criteria: * Age ≥18 years * RA diagnosis according to ACR (classification of rheumatoid arthritis) 1987 and/or ACR/EULAR 2010 criteria, validated by a senior rheumatologist * ILD diagnosis based on typical High-Resolution Computed-Tomography (HCRT) patterns and pulmonary function tests (PFT), validated by a senior pulmonologist Exclusion Criteria: \- Lack of signed informed consent SELECTION OF CONTROLS: Inclusion Criteria: * Age ≥18 years * RA diagnosis according to ACR 1987 and/or ACR/EULAR 2010 criteria, validated by a senior rheumatologist Exclusion Criteria: \- Lack of signed informed consent

Primary outcome measure(s)

  • Identification of genetic factors implicated in RA-ILD using whole exome sequencing (WES). — Baseline
    whole exome sequencing data

Trial sites (1)

FacilityCityRegionStatus
Bichat Hospital Paris France

More Assistance Publique - Hôpitaux de Paris trials in France

Analysis of the Influence of Gastric By-Pass on the Pharmacokinetics of Common Drugs Starting soon
Electrophysiological Analysis of Gamma-Hydroxybutyrate-induced Sleep in Intensive Care Patients Starting soon
Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL) Recruiting
French Cohort of Myocardial Infarction Evaluation Recruiting
Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine Recruiting

Other trials for the same condition

dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound Recruiting
The Medacta International GMK Sphere Cementless Post-Marketing Surveillance Study Active, not recruiting
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Active, not recruiting
Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension Treatment Recruiting
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04227535 on ClinicalTrials.gov ↗ ← All trials in France